Disease modification is not all — we need symptomatic therapies for Alzheimer disease
Nature Reviews Neurology, Published online: 25 November 2021; doi:10.1038/s41582-021-00591-9A new study found methylphenidate to be effective in treating apathy in individuals with Alzheimer disease. At a time when the recent aducanumab approval is focusing attention on the promise of disease-modifying therapies, the new findings highlight the importance of developing better symptomatic treatment options for individuals with psychiatric disorders of Alzheimer disease.
Source: Nature Reviews Neurology - Category: Neurology Authors: Jeffrey Cummings Source Type: research
More News: Alzheimer's | Brain | Concerta | Methylphenidate | Neurology | Psychiatry | Ritalin | Study